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and the common consequences were fractures and head injuries.
The common bones fractured were the radius and ulna.
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E-PRESCRIBING REDUCES BEERS PRESCRIBING AMONG 
THE ELDERLY
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OBJECTIVES: The objective of this study was to assess the
impact of a PDA-e-prescribing tool (e-tool) on prescribing poten-
tially inappropriate drugs from the Beers List to the elderly. The
Beers List documents potentially inappropriate medications that
should be avoided or used with caution in patients over the age
of 65 years. METHODS: All prescription claims (N = 383,855)
from April 2002 through June 2005 were extracted for 14,557
plan participants aged 65 and older in which 70 of 3706 pre-
scribers received an e-tool. For each claim, we identiﬁed whether
the prescription was new and a Beers listed drug and whether
the prescriber was an e-tool user and a staff model physician. E-
tool use was split into before and after initiation. New prescrip-
tions were classiﬁed into 6 and 12-month variables using prior
eligibility. Rates were determined as Beers claims counts divided
by total claims. We ran chi-square tests and logistic regressions
incorporating these and selected demographic variables.
RESULTS: After initiating e-tool use, providers prescribed sig-
niﬁcantly fewer Beers drugs than before across all (7.87% vs.
9.13%, p < 0.0001) and new (6-month: 3.39% vs. 4.68%, p <
0.0056; 12-month: 3.05% vs. 4.78%, p < 0.0025) prescriptions;
their before rates did not differ signiﬁcantly from non-e-tool
providers (overall: 9.09% vs. 9.13%, p = 0.8702; 6-month:
5.04% vs. 4.66%, p = 0.5459; 12-month: 3.05% vs. 4.78%, 
p < 0.9317). Staff providers prescribed signiﬁcantly fewer Beers
drugs overall than non-staff providers (8.88% vs. 9.27%, p =
0.0002), but not for 6-month (5.08% vs. 4.49%, p = 0.0558) or
12-month (4.97% vs. 4.69%, p = 0.5816) new prescriptions.
Regressions, accounting for provider degree and specialty, par-
ticipant sex and age group, and geography, yielded similar
results. CONCLUSION: e-Tools providing Beers criteria can sig-
niﬁcantly reduce the prescribing of these drugs among the elderly.
Such reductions have been shown to reduce morbidity, mortal-
ity, and health care costs.
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OBJECTIVES: The objective of this study was to identify the
most cost-effective oral or transdermal contraceptives (CCs)
using a provider perspective. METHODS: A decision analytic
model was developed to compare the cost-effectiveness of oral
CCs, 3 mg drospirenone/0.02 mg Ethinylestradiaol (DRSP-EE),
0.18 mg norgestimate/0.025 mg ethinylestradiol (NO-EE), and 
1 mg norethindrone acetate/20 mcg ethinyl estradiol (NA-EE);
transdermal CC 6 mg norelgestromin/0.075 mg ethinyestradiol
(transdermal N-EE); and no contraceptive use in preventing a
pregnancy per patient per year. Direct medical costs were based
on average wholesale prices for drugs (Wolters-Kluwer, 2006),
and, physician, laboratory and hospital costs based on 2006
Medicare reimbursement rates. Probability data that included
compliance and pregnancy rates were extracted from random-
ized clinical trials and public resources such as the 2002 National
Survey of Family Growth. A probabilistic sensitivity analysis of
all free parameters was conducted through a Monte Carlo sim-
ulation. Key parameters were sampled from beta distributions.
RESULTS: In the base case, DRSP-EE was found to be the most
cost-effective strategy. DRSP-EE cost $688 compared to $766 for
NA-EE, $736 for transdermal N-EE, and $729 for NO-EE to
prevent a single pregnancy per patient per year. No contracep-
tive use was the least cost-effective strategy, resulting in approx-
imately $52,529 to prevent a single pregnancy per patient per
year. Monte Carlo sensitivity analysis conﬁrmed these ﬁndings.
Incremental cost-effectiveness analyses revealed that the use of
transdermal N-EE costs an additional $86,285 per patient per
year to be as effective as DRSP-EE. CONCLUSION: In terms of
cost-effectiveness, DRSP-EE dominated all contraceptive strate-
gies. The overarching component driving differences in cost-
effectiveness was related to direct medical costs associated with
pregnancy. These direct medical costs, in turn, were driven by
differential compliance and efﬁcacy rates that favored DRSP-EE.
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OBJECTIVES: Estimate annual direct (medical expenditure) and
indirect (absenteeism and short-term disability) costs for women
with uterine ﬁbroids (UF). METHODS: We compared 12-month
direct costs among women aged 18–54 with clinically-signiﬁcant,
symptomatic UF (admission, emergency visit, or >2 ofﬁce visits
>30 days apart with a UF diagnosis) to a 1 : 1 propensity score
matched cohort of women without UF, using the MarketScan
Commercial Claims and Encounters insurance database data
from for 2000–2004. We also compared indirect costs for the
sub-sample of women with available data. Exponential condi-
tional regression analysis controlled for confounding factors, and
costs were adjusted to 2004 levels. RESULTS: Sample sizes for
the direct and indirect costs analyses were 38,020 and 1820,
respectively. Mean 12-month direct costs for women in the UF
group were $11,720 vs. $3257 for controls (women without
diagnosed or treated ﬁbroids). Mean 12-month indirect costs
were $11,752 and $8083 for women in the UF group and con-
trols, respectively. Estimated direct costs attributable to UF were
therefore $8463 (p < 0.001) and indirect costs were $3669 (p <
0.001). Employers’ share of direct costs ranged from 84.1% to
87.5%. CONCLUSION: Direct and indirect costs of uterine
ﬁbroids represent a substantial burden to employers. Treatment
options aimed at reducing symptoms and resultant absenteeism
are needed to improve women’s health and productivity.
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OBJECTIVES: To estimate the direct cost of surgical interven-
tions for Pelvic Organ Prolapse (POP) to the payers in Germany,
France and the National Health Service (NHS) in England.
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METHODS: We analyzed the 2004 German InEK Hospital sta-
tistics data, the 2005 French Programme de Médicalisation des
Systèmes d’Informations (PMSI) database and the 2005–06 NHS
England Hospital Episode Statistics (HES) database to estimate
the number and type of surgical procedures for POP. We included
procedures performed for uterovaginal prolapse, such as col-
porrhaphy, sacrocolpopexy and sacrospinous colpopexy. Addi-
tionally, we identiﬁed the total number of hysterectomies;
extrapolating from previous studies, we assumed 15% of these
were performed for a primary indication of POP. We multiplied
the observed number of surgical procedures by the respective
2007 Diagnosis-Related Group (DRG) reimbursement rates to
estimate the direct annual surgical cost. RESULTS: Annually,
62,581 POP repair procedures were performed in Germany,
32,392 in France and 23,583 in NHS England. In addition, we
estimate that 39,329 hysterectomies are performed for a primary
indication of POP across the three healthcare systems. The direct
surgical cost of these surgical procedures was €476M. CON-
CLUSIONS: The annual direct surgical cost of POP to the 3 big
European healthcare systems is nearly €500M, highlighting a sig-
niﬁcant burden to the European payer. This is under-estimate of
the true cost of the illness because it does not include other
medical costs, cost of conservative management and societal
costs. Extrapolating from epidemiological studies, about 30% of
POP procedures are repeat surgeries, implying the direct surgi-
cal cost of re-operations is approximately €135M. Considering
the high ﬁnancial burden of POP and its recurrence, it is imper-
ative that new standardized procedures with superior outcome
are considered, in order to effectively treat the condition, and by
doing so, reduce recurrence.
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OBJECTIVES: In 2001, excessive uterine bleeding was the cause
of 1.4 million physician visits in the US. Beyond offering con-
traceptive beneﬁts, Levonorgestrel-Releasing Intrauterine System
(LNG-IUS) is an effective alternative to traditional management
of menstrual bleeding disorders. The objective was to describe a
population on LNG-IUS and assess contraceptive and non-
contraceptive outcomes. METHODS: Women °Y´18 years of age
with LNG-IUS and °Y´1 year of continuous enrollment pre- and
post-insertion were identiﬁed via a retrospective cohort design
utilizing claims data from a Michigan vertically integrated health
care system (Jan. 2000–Dec. 2005). Patterns of LNG-IUS use,
number of obstetric- and gynecology-related visits, percent of
patients with menorrhagia, dysmenorrhea, dysfunctional uterine
bleeding, and abnormal uterine bleeding were compared pre- and
post-insertion, along with gynecology-related costs. RESULTS:
A total of 152 women (mean age 35 ± 8) met study inclusion
criteria. Two nested cohorts were distinguished further based on
follow-up length as 2-year pre/post (N = 73) and 3-year pre/post
(N = 29) groups. Over 90% had a single insertion and °Ü4% a
LNG-IUS -related complication (e.g. expulsion, perforation, or
infection). No LNG-IUS patient experienced a pregnancy with
no obstetric-related visits post-insertion for all groups. Thirteen
percent of women experienced menorrhagia in the year preced-
ing insertion, down to 12.5%, 1.2% and 0% in the 1, 2 and 3
years post-insertion. Subsequently, mean number of gynecology-
related visits decreased from 4 to 2; 7 to 4 and 9 to 4 from the
pre- to the post-insertion period for the 1, 2, and 3-year follow-
up groups, respectively. Among non-hysterectomized women,
mean gynecology-related costs decreased from $1646 per patient
in the 3 years preceding LNG-IUS to $1355 in the 3 years post-
insertion. CONCLUSION: LNG-IUS avoided pregnancy in all
patients and led to decreased bleeding-related events and gyne-
cology-related costs starting in the second year post-insertion.
Beneﬁts should become more apparent with longer follow-up.
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OBJECTIVES: Benzodiazepines are commonly prescribed for
older people. As the elderly are more susceptible to potential
adverse outcomes from benzodiazepines, it is recommended that
benzodiazepines be used for short periods with a reduced dosage.
This observational study aimed to investigate benzodiazepine
use, in terms of treatment period and mean dosage, and examine
characteristics associated with use. METHODS: This was an
observational study of randomly selected subjects enrolled in the
National Health Insurance program, aged at least 65, who
received at least one prescription for benzodiazepines in 2002.
They were grouped according to treatment period and mean
dosage. The treatment period was deﬁned as the number of days
covered by prescribed benzodiazepines. The mean dosage was
deﬁned by the average deﬁned daily dose (DDD) of each indi-
vidual. An ordered logit regression model was adopted to eval-
uate associations of characteristics with benzodiazepine usage.
RESULTS: Of the 17,024 elderly persons included, a total of
7451 had received at least one prescription for benzodiazepines.
Individuals with comorbid mental disease such as insomnia,
anxiety, and depression, and comorbid physical disease such as
cardiovascular disease, cancer, and renal disease, and previous
receipt of benzodiazepines were more likely to receive benzodi-
azepine prescriptions. Those older than 75 years, male, with
insomnia, anxiety, depression, mental disease, physical disease
such as cardiovascular disease and diabetes, previous receipt of
benzodiazepines, and higher prescription-overlap ratio were
more likely to receive longer treatment. Subjects with insomnia,
anxiety, depression, other mental disease, arthritis, previous
receipt of more benzodiazepines, and higher prescription-overlap
ratio were more likely to receive higher-dose therapy. CON-
CLUSION: According to our preliminary ﬁndings, the one-year
prevalence of benzodiazepine use among the elderly was approx-
imately 44%. Mental disorders, previous exposure to more 
benzodiazepine, and higher prescription-overlap ratio were asso-
ciated with both longer treatment and higher mean daily dose.
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OBJECTIVES: With the implementation of Medicare Part D,
managed care plans have aggressively marketed their offerings,
potentially expanding the proportion of beneﬁciaries enrolled in
Medicare managed care, known as Medicare Advantage (MA).
Growth in MA penetration has potentially important implica-
